Navigation Links
Profectus BioSciences Inc. Names Shawn Patrick O'Brien CEO
Date:1/28/2008

raduate School of Business at Harvard University.

"Shawn has had many successes leading the commercialization of both small and large molecules in the bio-pharmaceutical sector. We look forward to working with him to accelerate the Company's progress in developing products to prevent and treat viral diseases," concluded Caldwell.

About Profectus BioSciences Inc.

Profectus BioSciences Inc. began operations in early 2005 to develop and commercialize technologies to reduce the morbidity and mortality caused by human viral diseases, including the human immunodeficiency virus (HIV), the causative agent of AIDS. Founded to fulfill the mission of its co-founders Drs. Gallo, Blattner, and Redfield (collectively, the founders) for "bench- top-to-bedside" medicine, the Company applies its specific scientific expertise to help commercialize promising unique technologies used for human and animal health. For more information please visit: http://www.profectusbiosciences.com.

MEDIA CONTACTS:

Jeff Meshulam Kevin Jurrens (for Profectus

Profectus BioSciences BioSciences)

443-543-5010 Garfield Group Public Relations

meshulam@profectusbiosciences.com 215-867-8600 (x273)

kjurrens@garfieldgroup.com


'/>"/>
SOURCE Profectus BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Marshall, MN (PRWEB) , ... July 31, 2015 , ... ... Ralco Enrichment Center at the Lyon County Fair to be held August 5-9 in ... more about where their meals come from and how agriculture impacts their daily lives. ...
(Date:7/30/2015)... ... 30, 2015 , ... The 2015 Market Research Report on the Global ... the global Propanol market with a focus on the Chinese situation. Major companies included ... Oxea, ISU Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , ...
(Date:7/30/2015)... DIEGO, July 30, 2015   Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... industries, today reported financial results for the second quarter ... of 2015, we remain on track to achieve our ... Chief Executive Officer of the Company. "Since our last ...
(Date:7/30/2015)... WARRINGTON, Pa. , July 30, 2015 /PRNewswire/ ... announced that it has received the second $1.0M ... Business Innovation Research (SBIR) grant valued at up ... the company,s aerosolized KL4 surfactant as a potential ... lung injury.  Discovery Labs was awarded an initial ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... 21 Boston,Scientific Corporation (NYSE: BSX ) ... patients from its TAXUS ARRIVE 1 and 2 ... Express2(TM) Paclitaxel-Eluting,Coronary Stent System in "real-world" practice. The ... events and repeat,revascularization through two years in complex ...
... Part of AACR Virtual Meeting -, LOS ANGELES, ... today announced that Kathleen Danenberg, the Company,s,President and Chief ... pharmacogenomics in tailoring medicine at the 2007 AACR-NCI-EORTC,International Conference ... October 22-26, 2007 at the Moscone Convention Center,West in ...
... Keynote Luncheon Address by James Cornelius, CEO of ... VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH) today announced ... VioQuest,Pharmaceuticals, will be presenting at the Paramount BioSciences ... EDT at the Waldorf Astoria,Hotel in New York ...
Cached Biology Technology:ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 2ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 3ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients 4Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 2Response Genetics' CEO to Discuss Advances in Optimizing Therapy through Pharmacogenomics as Part of a Series of Presentations at AACR-NCI-EORTC International Conference 3VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference 2VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference 3
(Date:7/31/2015)... China , 31 de julio de 2015 ... www.icg-10.org ) se celebrará por medio de BGI del 22 al ... . Este año, la conferencia celebra ... ICG se ha convertido en una de las reuniones anuales ... ser una de las reuniones más dinámicas, entusiastas y mejores ...
(Date:7/27/2015)... 27, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Huawei has selected the Synaptics ... its stylish smartwatch. Huawei chose the state-of-the-art ClearPad ... power and highly responsive human interface qualities such ... also required a classic round watch face and ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... has released the final "Integrated Science Assessment for Oxides ... of the scientific literature on the potential adverse human ... particularly nitrogen dioxide or NO2. There are significant ... scientific review document released in 1993. Oxides ...
... in Spanish . Cancer is a ... adaptative changes give higher proliferative capacity to cancer cells, ... agents. The research group led by Dr. Jos Carlos ... the CSIC (IIBB-CSIC), a centre linked to the Institut ...
... IMMEDIATE RELEASE Detecting flu viruses in remote areas of ... Researchers in Ohio and New Mexico are reporting an advance ... viruses one that requires no refrigeration and can be used ... emerge. Their new method, the first to use sugar molecules rather ...
Cached Biology News:Mitochondrial cholesterol makes response to chemotherapy difficult in hepatic cancer 2American Chemical Society's Weekly PressPac -- July 9, 2008 2American Chemical Society's Weekly PressPac -- July 9, 2008 3American Chemical Society's Weekly PressPac -- July 9, 2008 4American Chemical Society's Weekly PressPac -- July 9, 2008 5American Chemical Society's Weekly PressPac -- July 9, 2008 6American Chemical Society's Weekly PressPac -- July 9, 2008 7American Chemical Society's Weekly PressPac -- July 9, 2008 8American Chemical Society's Weekly PressPac -- July 9, 2008 9
Ready-to-use solution....
...
... Conjugated peptides or recombinant proteins ... to produce antibodies in 2 rabbits. pre-immune ... ELISA test until the titer reaches 1:4,000 ... Protein G purification Antibodies are eluted ...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: